60 DEGREES PHARMACEUTICALS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that 60 DEGREES PHARMACEUTICALS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.01M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $607.6K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $253.6K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $223.2K | Apr 1, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $223.8K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $222.8K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($221.0K) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($209.2K) | Apr 1, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.37M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($7.95M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($3.77M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($6.18M) | Apr 1, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.76M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($9.72M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($5.15M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($1.75M) | Apr 1, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.11M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $4.99M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $691.8K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $525.6K | Apr 1, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.85M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($5.65M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($4.54M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($1.01M) | Apr 1, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $139.9K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $103.8K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $57.6K | Mar 27, 2025 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.37M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $5.76M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $7.78M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.30M | Apr 1, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.99M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.80M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $2.99M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $25.45M | Apr 1, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.46M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $4.04M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $4.87M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($23.58M) | Apr 1, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($47.89M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($40.53M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($32.58M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($28.82M) | Apr 1, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.51M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.66M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $2.14M | Mar 27, 2025 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $150.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2024 | $150.0K | Mar 27, 2025 |
| FY2023 | Dec 31, 2023 | $150.0K | Apr 1, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (11) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (74) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (59) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Apr 1, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (11) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (74) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (59) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.16M | Mar 30, 2026 |
| FY2025 | Feb 24, 2025 | 1.47M | Mar 30, 2026 |
| FY2025 | Feb 18, 2025 | 7.36M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 141,749 | Mar 30, 2026 |
| FY2025 | Aug 12, 2024 | 1.77M | Mar 30, 2026 |
| FY2025 | Jul 30, 2024 | 21.22M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 96,847 | Mar 27, 2025 |